AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27779776
Drug: Sildenafil 10
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 10 mg as a bolus followed by 2.5 mg infusion over 2 hours
Trial: 27779776
Drug: Sildenafil doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil doses (2.5 mg, 5 mg, 10 mg)
Trial: 23601186
Drug: Oral paricalcitol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paricalcitol, 2 μg per day for the first year posttransplant
Trial: 23601186
Drug: Oral paricalcitol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paricalcitol, 2 μg per day
Trial: 16689086
Drug: Central neurotropic
RxNorm normalized name: brain-derived neurotrophic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central neurotropic preparations in addition to routine medicines
Trial: 16689086
Drug: Routine preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine preparations only
Trial: 29979803
Drug: Oxycodone and
RxNorm normalized name: oxycodone and naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone and acetaminophen PRN
Trial: 29979803
Drug: Oxycodone and
RxNorm normalized name: oxycodone and naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone and acetaminophen with specific dosing
Trial: 29979803
Drug: Oxycodone, acetaminophen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone, acetaminophen, and OxyContin with specific dosing
Trial: 29979803
Drug: Oxycodone, acetaminophen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone, acetaminophen, and ketorolac with specific dosing
Trial: 26190830
Drug: Subcutaneous agar‐filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous agar‐filled needle with calomel (Ndl)
Trial: 26190830
Drug: Dermal abrasion
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermal abrasion with conducting cream and Ag/AgCl electrodes (Abr)
Trial: 24636266
Drug: Standard guidelines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard guidelines for antibiotic therapy (Control)
Trial: 22120765
Drug: Nebulized L-epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized L-epinephrine 0.5 ml
Trial: 22120765
Drug: Nebulized L-epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized L-epinephrine 2.5 ml
Trial: 22120765
Drug: Nebulized L-epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized L-epinephrine 5 ml
Trial: 12187023
Drug: Interferon gamma-1b
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon gamma-1b (IFN-gamma), given subcutaneously at a dose of 50 microg/m(2) daily for 30 days.
Trial: 1767176
Drug: Troxerutin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troxerutin (4 g/d)
Trial: 30068263
Drug: Pomalidomide and
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide and low-dose dexamethasone
Trial: 23429358
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose)
Trial: 22819265
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (300 mg loading dose)
Trial: 19914566
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (5-FU) based adjuvant chemotherapy
Trial: 16296924
Drug: Kampo therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kampo therapy for 12 weeks
Trial: 8824645
Drug: Lactose (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (1 L of milk)
Trial: 8824645
Drug: Pre-hydrolyzed milk
RxNorm normalized name: collagen, hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-hydrolyzed milk and lactase preparations
Trial: 1775676
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release salbutamol (SCR) 8 mg twice daily for 6 weeks
Trial: 7318626
Drug: Cefamandole treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole treatment in 112 patients
Trial: 31395808
Drug: Animal-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-assisted therapy (kinesitherapy with therapy dog)
Trial: 31395808
Drug: Kinesitherapy (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesitherapy (without therapy dog)
Trial: 17582255
Drug: Esomeprazole-based 1
RxNorm normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole-based 1 week triple therapy
Trial: 17582255
Drug: Esomeprazole-based 2
RxNorm normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole-based 2 weeks triple therapy
Trial: 1907549
Drug: Piroxicam, 20
RxNorm normalized name: Piroxicam, 20 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam, 20 mg day‐1
Trial: 28629397
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of renal replacement therapy (RRT)
Trial: 28629397
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of renal replacement therapy (RRT)
Trial: 26926372
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human thrombopoietin (rhTPO) combined with high-dose dexamethasone (40 mg intravenously d1-4) and rhTPO (300 U·kg(‐1)·d(‐1) subcutaneously d1-14)
Trial: 26926372
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (40 mg intravenously d1-4)
Trial: 24570273
Drug: Tart cherry
RxNorm normalized name: Tart Cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tart cherry juice concentrate (30 ml diluted to 250 ml with water)
Trial: 17301566
Drug: HCV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV RNA < 50 IU/ml at week 4
Trial: 17301566
Drug: HCV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV RNA < 600 IU/ml at week 4
Trial: 17301566
Drug: HCV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV RNA > 50 IU/ml at week 4
Trial: 17301566
Drug: HCV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV RNA > 600 IU/ml at week 4
Trial: 11585082
Drug: Cisapride (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (0.2 mg/kg every 8 h)
Trial: 9827406
Drug: D-Dimer test
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Dimer test with a cutoff value below 2 micrograms/ml
Trial: 9827406
Drug: D-Dimer test
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Dimer test with a cutoff value over 4 micrograms/ml
Trial: 28511647
Drug: Traditional cookstove
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional cookstove (chulha) or a combination of traditional stove and kerosene/diesel stove
Trial: 24303810
Drug: Traditional Behavioral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Behavioral Couples Therapy (TBCT)
Trial: 24303810
Drug: Integrative Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative Behavioral Couples Therapy (IBCT)
Trial: 12553852
Drug: alefacept (0.025,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alefacept (0.025, 0.075, or 0.150 mg/kg)
Trial: 10674226
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention (daily distribution of two oral supplements, each containing 200 kcal for 15 days)
Trial: 8369008
Drug: Vitex agnus
RxNorm normalized name: VITEX AGNUS-CASTUS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitex agnus castus preparation (20 mg daily)
Trial: 2878676
Drug: Oral xamoterol
RxNorm normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral xamoterol (200 mg twice daily)
Trial: 10367991
Drug: I2‐imidazoline receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I2‐imidazoline receptor density in ATD patients (8.4 and 14.3 fmol/mg protein)
Trial: 10367991
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between I2‐imidazoline receptors and MAO‐B activity
Trial: 7884434
Drug: Amonafide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amonafide (300 mg/m2 daily for 5 days)
Trial: 21849147
Drug: Hirudoid cream
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudoid cream
Trial: 7458751
Drug: Various chemical
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various chemical agents administered to influence microcirculation and metabolism of the inner ear.
Trial: 7458751
Drug: NaCl infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl infusions and glucose tablets (control group).
Trial: 7458751
Drug: Polypragmatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypragmatic therapy (four different forms).
Trial: 31642928
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavior therapy for 16 weeks
Trial: 31642928
Drug: Face-to-face cognitive
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face cognitive behavior therapy for 16 weeks
Trial: 24440324
Drug: Evidence-based medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medications at discharge in high-income countries
Trial: 22523593
Drug: 1,2-octanediol lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,2-octanediol lotion (20% alcohol) applied for 2-2.5 hours
Trial: 22523593
Drug: 1,2-octanediol lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,2-octanediol lotion (20% alcohol) applied for 8 hours/overnight
Trial: 20673378
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet + placebo capsules
Trial: 20673378
Drug: 40 mmol
RxNorm normalized name: citrate 18 mmol / sodium 140 mmol in L Injection (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mmol potassium citrate capsules/d
Trial: 16115933
Drug: Doxil (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil (40 mg/m2 i.v. on day 1) and continuous infusion topotecan (0.4 mg/m2/day for 14 days)
Trial: 16115933
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan (0.4 mg/m2 bid for 14 days)
Trial: 16115933
Drug: Doxil with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil with 14‐day topotecan infusion
Trial: 16115933
Drug: Doxil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxil and continuous infusion topotecan
Trial: 10200009
Drug: Active immunotherapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active immunotherapy (cat/dust mite)
Trial: 10200009
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (active immunotherapy and placebo)
Trial: 6796106
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral cyclophosphamide (arm S)
Trial: 6796106
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral cyclophosphamide, hexamethylmelamine and methotrexate on a pulsed basis (arm T)
Trial: 27124881
Drug: Dexamethasone delayed
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone delayed delivery system monotherapy
Trial: 24535625
Drug: Luseogliflozin (1-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin (1-25 mg single dose)
Trial: 24535625
Drug: Luseogliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luseogliflozin (5 or 10 mg/day for 7 days)
Trial: 20862940
Drug: Shallow needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shallow needling combined with acupoint application on top of routine medication.
Trial: 20862940
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication (control group).
Trial: 19049703
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1,200 mg twice daily + bicarbonate hydration
Trial: 9364366
Drug: Intermittent testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent testosterone enanthate treatment (25‐100 mg every two weeks for three months)
Trial: 3971528
Drug: Control (drug-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (drug-free state)
Trial: 29516990
Drug: Thalidomide 150
RxNorm normalized name: thalidomide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 150 mg/day and cinobufagin 2700 mg/day
Trial: 29516990
Drug: Cinobufagin 2700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinobufagin 2700 mg/day (Control)
Trial: 26849844
Drug: SEP-432 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP-432 (300 mg/day)
Trial: 25391194
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg folic acid for 2 months
Trial: 18455727
Drug: Active pill
RxNorm normalized name: Factive Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active pill phase (oral contraceptives)
Trial: 15932917
Drug: PCOS patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCOS patients without metformin therapy
Trial: 12940609
Drug: Fluvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (20 mg) and dipyridamole (5 mg/kg) for 1 year
Trial: 12940609
Drug: Dipyridamole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (5 mg/kg) only for 1 year
Trial: 1763597
Drug: Heparin injection
RxNorm normalized name: heparin Injection
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin injection
Trial: 30169462
Drug: Valaciclovir 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 8 g daily
Trial: 15936423
Drug: Corticosteroids (methylprednisolone)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corticosteroids (methylprednisolone) administered via a 48-hour infusion
Trial: 1718250
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (argon green or krypton red lasers)
Trial: 20572378
Drug: Generic product
RxNorm normalized name: Generlac Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic product of a single oral 8 mg rosiglitazone tablet
Trial: 20572378
Drug: Innovator's product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovator's product of a single oral 8 mg rosiglitazone tablet
Trial: 12682308
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg per os twice a day)
Trial: 11110418
Drug: Herpes simplex
RxNorm normalized name: herpes simplex 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herpes simplex virus thymidine kinase/ganciclovir (HSV‐tk/GCV) gene therapy by direct intracerebral injection of retrovirus (RV) vector producing cells (VPC) during tumor surgery and subsequent systemic administration of GCV
Trial: 11110418
Drug: Herpes simplex
RxNorm normalized name: herpes simplex 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herpes simplex virus thymidine kinase/ganciclovir (HSV‐tk/GCV) gene therapy
Trial: 11110418
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not receiving HSV‐tk/GCV gene therapy)
Trial: 1922908
Drug: Frusemide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 0.5 mg/kg body weight (Study 1)
Trial: 1922908
Drug: Frusemide 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 1.0 mg/kg body weight (Study 2)
Trial: 29615172
Drug: Trabeculectomy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trabeculectomy without adjunctive mitomycin C
Trial: 22823552
Drug: Pharmacist-delivered medication
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-delivered medication therapy management (MTM) intervention
Trial: 18544146
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.03 mcg.kg(‐1).min(‐1)
Trial: 7834970
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (100% humidified at 101/min for 8-10 h prior to ultrasound)
Trial: 1972836
Drug: EMLA 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA 2% cream
Trial: 25075
Drug: Oxprenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol (100 mg)
Trial: 31523169
Drug: Yunnan Baiyao
RxNorm normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yunnan Baiyao (YB) treatment
Trial: 27990643
Drug: CN-105 (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CN-105 (active treatment)
Trial: 26030115
Drug: Nonhorticultural occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonhorticultural occupational therapy (OT)
Trial: 31220560
Drug: Bushen capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen capsules (BSC)
Trial: 25503617
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU) administered twice daily for 1 week
Trial: 25503617
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (48 IU) administered twice daily for 1 week
Trial: 25503617
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (72 IU) administered twice daily for 1 week
Trial: 19351734
Drug: Arzoxifene 20
RxNorm normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arzoxifene 20 mg/d
Trial: 1756116
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of UVA (80‐160 J/cm2; 340‐440 nm) after treatment
Trial: 6187065
Drug: Disopyramide retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide retard (DR) 2 X 300 mg/day
Trial: 6187065
Drug: Propranolol retard
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Avlocardyl Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol retard (PR) 1 X 160 mg/day
Trial: 31606753
Drug: D-fortified sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-fortified sunflower oil (500 IU/30 g)
Trial: 27575992
Drug: HB-C (home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB-C (home-based computer vergence/accommodative therapy)
Trial: 27575992
Drug: HB-PU (home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB-PU (home-based near target push-up therapy)
Trial: 27575992
Drug: HB-P (home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB-P (home-based placebo treatment)
Trial: 18315940
Drug: Intramuscular IFNbeta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular IFNbeta‐1a (Avonex) 30 microg once weekly
Trial: 18315940
Drug: Subcutaneous IFNbeta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IFNbeta‐1a (Rebif) 44 microg three times per week
Trial: 19444734
Drug: Behavioral Naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Naltrexone Therapy
Trial: 19444734
Drug: Intensive behavioral
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive behavioral therapy
Trial: 10726104
Drug: 1.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 g/day of LC n‐3 PUFA
Trial: 8530611
Drug: Potassium bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium bicarbonate (KHCO3, 2 meq/kg/day in divided doses)
Trial: 25422026
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone therapy combined with physical training